NEW ORLEANS (March 2, 2026)—The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including semaglutide, has expanded rapidly among patients … Continue reading Studies explore: GLP-1 receptor agonist use and its impact on long-term musculoskeletal health